市場調查報告書
商品編碼
1396578
智慧吸入器市場 - 按產品、疾病適應症、配銷通路- 全球預測,2023-2032 年Smart Inhalers Market - By Product, By Disease Indication, By Distribution Channel - Global Forecast, 2023-2032 |
由於全球呼吸系統疾病盛行率激增,智慧吸入器市場規模預計從 2023 年到 2032 年將以 8.6% 的複合CAGR擴大。
隨著氣喘和慢性阻塞性肺病 (COPD) 等疾病負擔的不斷加重,對先進呼吸護理解決方案(尤其是智慧吸入器)的需求正在激增。根據 2023 年 CDC 報告,慢性阻塞性肺病每年影響美國超過 1,600 萬人。智慧吸入器透過劑量提醒和即時監控等功能提高藥物依從性。此外,隨著醫療保健領域擁抱遠距醫療和遠距患者監控,市場必將獲得巨大的發展動力。
該行業分為產品、疾病適應症、配銷通路和地區。
從產品來看,基於MDI 的智慧吸入器市場在2022 年獲得了巨大的吸引力,預計到2032 年將實現9.1% 的成長率。基於MDI 的智慧吸入器將技術與傳統吸入設備相結合,以增強藥物依從性和監測。這些智慧吸入器還有助於為患者提供即時資料追蹤、劑量提醒和個人化見解,以改善整體呼吸管理。 MDI 設備的使用者友善性與數位連接的優勢相結合也將促進該細分市場的成長。
就配銷通路而言,由於呼吸系統疾病負擔日益加重以及人們對便捷醫療解決方案的日益青睞,電子商務領域的智慧吸入器市場預計將在 2023 年至 2032 年間以 10% 的CAGR產生可觀的收入。比較產品、閱讀用戶評論和線上獲取資訊的便利性正在增強消費者的決策能力。此外,數位健康和遠距醫療的上升趨勢可能會推動該領域的擴張。
從地區來看,2023 年至 2032 年歐洲智慧吸入器產業的複合CAGR預計將達到 8.9%。該地區先進的醫療基礎設施以及呼吸道疾病的高發病率正在促進創新呼吸護理解決方案的採用。此外,製藥公司和科技公司持續投資開發與數位技術相結合的智慧吸入器,以有效管理氣喘和慢性阻塞性肺病,以及增加患者參與計劃,將加速區域產業的擴張。例如,2023 年 7 月,梯瓦製藥 (Teva) 在英國推出了新型數位化吸入器,用於治療氣喘和慢性阻塞性肺病 (COPD) 患者。
Smart Inhalers Market size is set to expand at 8.6% CAGR from 2023-2032 attributed to the surging prevalence of respiratory conditions globally.
With the rising burden of conditions like asthma and chronic obstructive pulmonary disease (COPD), the demand for advanced respiratory care solutions, particularly smart inhalers, is surging. According to the 2023 CDC reports, COPD affects over 16 million individuals in the U.S. every year. Smart inhalers offer improved medication adherence through features, such as dosage reminders and real-time monitoring. Furthermore, with the healthcare landscape embracing telemedicine and remote patient monitoring, the market is set to gain significant momentum.
The industry is segmented into product, disease indication, distribution channel, and region.
Based on product, the MDI-based smart inhalers market gained significant traction in 2022 and is anticipated to witness 9.1% growth rate through 2032. MDI-based smart inhalers integrate technology with traditional inhalation devices for enhancing medication adherence and monitoring. These smart inhalers also facilitate real-time data tracking, dosage reminders, and personalized insights for patients for improving the overall respiratory management. The user-friendly nature of MDI devices combined with the benefits of digital connectivity will also contribute the segment growth.
In terms of distribution channel, the smart inhalers market from the e-commerce segment is projected to generate considerable revenue at 10% CAGR between 2023 and 2032 attributed to the rising burden of respiratory conditions and the increasing preference for convenient healthcare solutions. The ease of comparing products, reading user reviews, and obtaining information online is leading to enhanced consumer decision-making. Moreover, the rising trend of digital health and telemedicine is likely to fuel the segment expansion.
Regionally, the Europe smart inhalers industry is set to witness robust growth at 8.9% CAGR from 2023-2032. The presence of sophisticated healthcare infrastructure coupled with a high prevalence of respiratory diseases in the region is fostering the adoption of innovative respiratory care solutions. Additionally, the ongoing investments by pharmaceutical companies and technology firms for the development of smart inhalers integrated with digital technologies for effective management of asthma and COPD along with increased patient engagement initiatives will accelerate the regional industry expansion. For instance, in July 2023, Teva unveiled its new digitally enabled inhaler in the U.K. for patients suffering from asthma and COPD.